Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Limb-Girdle Muscular Dystrophy (LGMD): Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report provides a data ...

During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...

Limb-girdle muscular dystrophies constitute a broad range of clinical and genetic entities. We have evaluated 38 autosomal recessive limb-girdle muscular dystrophy (LGMD2) families by linkage analysis ...

This December, hundreds of NFL players are donning custom-designed cleats as part of the 8th annual My Cause My Cleats campaign, spotlighting ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

This Friday, November 29, the Spirit of Christmas concert returns to Belfast for a sixth year to raise money for Muscular ...

One thing that sticks with me is how earnest the documentary feels. Steen was both a dear and considerate friend to the ...

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

Full functional recovery has been achieved in an entire muscle using AAV vector-mediated gene therapy in a limb girdle muscular dystrophy hamster model, which has a mutation in the 1.2-kb gene for ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.